FOXO4-DRI What Is It? A Senolytic With Awkward Numbers

Start with the figures that can be verified independently, because they anchor everything else.

Note the last two rows against the first four. The molecule is precisely characterised and entirely unstudied in people, which is an unusual combination and the source of most confusion about it.

The names differ by three characters and the things they name are entirely different.

FOXO4 is a protein your body makes, a transcription factor in the FOXO family involved in stress resistance, metabolism and cell-cycle control. It is ordinary human biology.

FOXO4-DRI is a synthetic peptide built to interfere with what FOXO4 does inside senescent cells. It is not a supplement version of a natural protein and your body does not produce it.

So a search for FOXO4 versus FOXO4-DRI compares a human transcription factor with a designed tool intended to block it. Note also the fourth character: it is the letter O, from Forkhead box protein O4. Several vendors render it as a digit zero, including in product URLs, which is a typo that propagated rather than a different product.

The DRI suffix describes construction rather than function, and it is the reason the molecule is viable at all.

Ordinary peptides are chains of L-amino acids, the form biology uses, which also makes them exactly what your proteases are built to digest. A D-retro-inverso peptide reverses two properties at once: the amino acids are the mirror-image D form, and the sequence is assembled backwards. The combination presents side chains in roughly the same spatial arrangement as the original, so it still engages the same binding partner, while being much harder for enzymes to recognise and cleave.

There is an analytical consequence worth knowing when reading a certificate. A D-retro-inverso peptide contains the same atoms as its natural counterpart, so it has the same mass. Mass spectrometry confirms composition but not stereochemistry, which means an identity check by mass alone does not distinguish the D form from the L form.

Cells that accumulate damage can enter senescence, a permanent exit from the cell cycle. They stop dividing but do not die, remaining metabolically active and secreting inflammatory cytokines and proteases. They accumulate with age.

The puzzle the 2017 work solved was why these cells do not simply undergo apoptosis given their damage load. The answer was FOXO4: in senescent cells it binds p53 and holds it in a configuration that prevents it triggering cell death.

FOXO4-DRI is a decoy. It occupies the site where FOXO4 would bind p53, displacing the interaction. Freed, p53 relocates out of the nucleus and the cell dies. Healthy cells are largely unaffected because they are not relying on that interaction to survive, and that differential is the selectivity the approach depends on. A 2025 paper identified the binding target more precisely as the disordered transactivation domain of p53.

Given how exactly the molecule is specified, the imprecision downstream is striking.

The first row is the one this site can help with directly: work from the certificate for your lot, not the label, and put that figure into the calculator rather than the printed 10 mg.

The rest are gaps that no amount of arithmetic closes. Senolysis is also not uniformly beneficial: a 2023 study found that clearing senescent cells could promote pulmonary hypertension, so the mechanism cuts in more than one direction.